scholarly journals Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015

2018 ◽  
Vol 7 (11) ◽  
pp. 394 ◽  
Author(s):  
Meng-Tzu Weng ◽  
Chien-Chih Tung ◽  
Yuan-Ting Chang ◽  
Yew-Loong Leong ◽  
Yu-Ting Wang ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis B ◽  
Bowel Disease ◽  
Dosage Group ◽  
Aminosalicylic Acid ◽  
High Dosage Group ◽  
Asian Patients ◽  
Tnf Α ◽  
Long Term Follow Up ◽  
Inflammatory Bowel

Background: No nationwide, long-term follow-up study has assessed medication-associated outcomes for Asian patients with inflammatory bowel disease (IBD). This study examined medication-associated outcomes for Taiwanese patients with IBD. Methods: In this nationwide cohort study, 3806 patients who had received catastrophic illness registration for IBD from 2001 to 2015 were enrolled. Results: A higher accumulated dosage of 5-aminosalicylic acid (5-ASA) was associated with decreased risks of hospitalization (hazard ratio (HR) = 0.6) and operation (HR = 0.5). Thiopurine was associated with increased risks of hospitalization (HR = 2.1 in the high-dosage group) and tuberculosis (TB; HR = 3.6) reactivation but not with operation risk. A higher accumulated dosage of anti-TNF-α agents was associated with increased risks of hospitalization (HR = 3.3), operation (HR = 2.9), hepatitis B (HR = 4.3), and TB (HR = 5.1) reactivation. Corticosteroids were associated with increased risks of hospitalization (HR = 3.5 in the high-dosage group), risk of operation, hepatitis B (HR = 2.8) and TB (HR = 2.8) reactivation. Conclusions: 5-ASA usage is associated with decreased risks of hospitalization and operation for patients with IBD, whereas thiopurine, corticosteroids, and anti-TNF-α agents are associated with increased risks of hospitalization and hepatitis B and TB reactivation.

scholarly journals Cutaneous Manifestations in Biological-Treated Inflammatory Bowel Disease Patients: A Narrative Review

2021 ◽  
Vol 10 (5) ◽  
pp. 1040
Author(s):  
Jo L. W. Lambert ◽  
Sofie De Schepper ◽  
Reinhart Speeckaert
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Cutaneous Manifestations ◽  
Cutaneous Infections ◽  
Tnf Α ◽  
Common Skin ◽  
Receptor Blockers ◽  
Infusion Reactions ◽  
Inflammatory Bowel ◽  
Lichenoid Reactions

The biologic era has greatly improved the treatment of Crohn’s disease and ulcerative colitis. Biologics can however induce a wide variety of skin eruptions, especially those targeting the TNF-α and Th17 pathway. These include infusion reactions, eczema, psoriasis, lupus, alopecia areata, vitiligo, lichenoid reactions, granulomatous disorders, vasculitis, skin cancer, and cutaneous infections. It is important to recognize these conditions as treatment-induced adverse reactions and adapt the treatment strategy accordingly. Some conditions can be treated topically while others require cessation or switch of the biological therapy. TNF-α antagonists have the highest rate adverse skin eruptions followed by ustekinumab and anti-integrin receptor blockers. In this review, we provide an overview of the most common skin eruptions which can be encountered in clinical practice when treating IBD (Inflammatory bowel disease) patients and propose a therapeutic approach for each condition.

Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Gut ◽  
2010 ◽  
Vol 59 (10) ◽  
pp. 1340-1346 ◽  
Author(s):  
C. Loras ◽  
J. P. Gisbert ◽  
M. Minguez ◽  
O. Merino ◽  
L. Bujanda ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis B ◽  
Immunosuppressive Therapy ◽  
Liver Dysfunction ◽  
Bowel Disease ◽  
Inflammatory Bowel

Sa1124 A Report on the Prevalence and Reactivation Rate of Hepatitis B Virus in Patients With Inflammatory Bowel Disease in Japan

2014 ◽  
Vol 146 (5) ◽  
pp. S-206
Author(s):  
Yoko Yokoyama ◽  
Mikio Kawai ◽  
Koji Kamikozuru ◽  
Masaki Iimuro ◽  
Nobuyuki Hida ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Bowel Disease ◽  
B Virus ◽  
Inflammatory Bowel

scholarly journals Hepatitis B Virus Reactivation Induced by Infliximab Administration in a Patient with Crohn’s Disease

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Yuka Miyake ◽  
Aki Hasebe ◽  
Tetsuya Tanihira ◽  
Akiko Shiraishi ◽  
Yusuke Imai ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Crohn’S Disease ◽  
Hepatitis B Virus ◽  
Crohn's Disease ◽  
Hepatitis B ◽  
Bowel Disease ◽  
Hbv Dna ◽  
Hbv Reactivation ◽  
B Virus ◽  
Inflammatory Bowel

A 47-year-old man diagnosed with Crohn’s disease was treated with infliximab. He tested negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) but positive for anti-HB core antibody (anti-HBc). He tested positive for hepatitis B virus (HBV-) DNA 3 months after treatment and was administered entecavir. HBV-DNA test showed negative results 1 month later. ALT was persistently within the normal range, and HBV-DNA was persistently negative thereafter despite the continuation of infliximab every 8 weeks. In our hospital, 14 patients with inflammatory bowel disease, who tested negative for HBsAg, were treated with infliximab; 2 of them tested positive for anti-HBs and/or anti-HBc, and HBV reactivation was observed in 1 patient (the present patient). The present case and these findings highlight that careful follow-up is needed in patients with inflammatory bowel disease treated with infliximab who test positive for anti-HBc and/or anti-HBs.

Sign in / Sign up

Export Citation Format

Share Document